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The direct oral anticoagulants (DOACs) provide a number of clinical advantages over vitamin K antagonists
for the treatment of thromboembolism, including improved efﬁcacy and safety, as well as no need for
regular monitoring of anticoagulant effect. However, as with all anticoagulants, bleeding complications may
occur, and anticoagulant reversal may be required in speciﬁc clinical situations, such as in patients expe-
riencing spontaneous or traumatic bleeds, or in anticoagulated patients requiring emergency surgery or other
invasive procedures. Therefore, several reversal agents for the DOACs are in development. This includes the
speciﬁc reversal agent idarucizumab, which has been approved by the U.S. Food and Drug Administration
and the European Medicines Agency for use in patients treated with dabigatran when urgent reversal of
its anticoagulant effects is needed. Idarucizumab is a humanized monoclonal antibody fragment that binds
with high afﬁnity to free and thrombin-bound dabigatran, resulting in an almost irreversibly bound idar-
ucizumabedabigatran complex and thereby neutralizing dabigatran’s anticoagulant activity. The reversal of
the anticoagulant effects of dabigatran by idarucizumab has been demonstrated in animal bleeding models,
in healthy volunteers with a range of ages and renal function, and in anticoagulated patients. In the phase 1
trials, at doses of 2 g or greater, idarucizumab resulted in immediate and complete reversal of the dabigatran
anticoagulant effects and was well tolerated. In the absence of dabigatran, idarucizumab showed no
effect on coagulation parameters or thrombin formation. These ﬁndings provide initial evidence that
idarucizumab could provide a safe and effective means of reversing anticoagulant activity in patients treated
with dabigatran in need of emergency surgery or in emergency bleeding situations.
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0.1016/j.amjmed.2016.06.007are alternatives to vitamin K antagonists (VKAs) for the
treatment of and reduction of risk from thromboembolic
disease.1-4 The DOACs have a number of clinical advan-
tages over VKAs, including a lower risk of intracranial
hemorrhage and a possible reduction in major bleeding-
associated mortality in patients with nonvalvular atrial
ﬁbrillation and in patients receiving acute treatment for
venous thromboembolism.5-7 However, as with all antico-
agulants, bleeding complications are still a concern, and
there is a need for anticoagulant reversal in speciﬁc clinicalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Reilly et al Idarucizumab: MOA/phase 1 Data S65situations, such as in patients experiencing spontaneous or
traumatic bleeds or in those requiring emergency surgery
or other invasive procedures. As a result, DOAC-speciﬁc
reversal agents have been developed for clinical situa-
tions, in which, urgent anticoagulation reversal is required.
These agents include idarucizumab (Boehringer
Ingelheim, Ridgeﬁeld, Conn), andexanet alfa (r-Antidote,
PRT064445; Portola Pharmaceuticals, South San Fran-
cisco, Calif), and ciraparantag (aripazine, PER-977; Pero-
sphere, Danbury, Conn). Idarucizumab is a monoclonal
antibody fragment that binds to the direct thrombin in-
hibitor dabigatran, thereby immediately reversing its anti-
coagulant effects.8 Andexanet alfa is an FXa decoy
molecule with no intrinsic coagulation activity that has
been designed to bind both direct FXa inhibitors and in-
direct FXa inhibitors (eg, fondaparinux and enox-
aparin).9,10 Ciraparantag is a potential antidote for direct
and indirect FXa inhibitors and direct thrombin inhibitors,
as well as unfractionated heparin and low-molecular-
weight heparins, such as enoxaparin.11
This review will focus on idarucizumab, which received
accelerated approval by the U.S. Food and Drug Adminis-
tration in October 2015 and the European Medicines
Agency in November 2015 for use in patients treated with
dabigatran when reversal of the anticoagulant effects of
dabigatran is needed (ie, for emergency surgery/urgent
procedures or if there is life-threatening or uncontrolled
bleeding).12,13BIOCHEMICAL COMPOSITION AND MODE OF
ACTION
Idarucizumab was identiﬁed by screening dabigatran-
speciﬁc monoclonal antibodies generated by immunizing
mice with dabigatran-derived haptens coupled to carrier
proteins. Monoclonal antibody fragments that were pro-
duced in Chinese hamster ovary cells were selected
according to potency of dabigatran-binding afﬁnity. These
were then humanized to minimize immunogenicity.8
With respect to the molecular recognition and binding of
dabigatran, idarucizumab has structural similarities to
thrombin, but idarucizumab lacks enzymatic activity
(Figure 1; please also see mode of action video in
supplemental materials).8,14 Idarucizumab’s binding to
dabigatran is mediated by hydrophobic interactions, H-
bonds, and a salt bridge, which result in a high afﬁnity for
dabigatran (dissociation constant [KD] 2.1  0.6 pM,
approximately 350-fold stronger than dabigatran’s afﬁnity
for thrombin).8 This high afﬁnity corresponds with a rapid
on rate and very slow off rate, resulting in an almost irre-
versible binding of idarucizumab to dabigatran.8,15 Despite
the structural similarities with thrombin, idarucizumab does
not bind to thrombin substrates, including FV, FVIII, FXIII,
or ﬁbrinogen. Furthermore, idarucizumab does not exhibit
thrombin-like activity, as demonstrated by a lack of activity
in coagulation or platelet aggregation tests.8 Idarucizumab
added to plasma in vitro did not alter clotting in the dilutedthrombin time (dTT) assay, nor shorten the clotting time of
prothrombin-depleted plasma. Idarucizumab did not convert
the main substrate of thrombin, ﬁbrinogen, into ﬁbrin, as
measured by ﬁbrinopeptide A (FPA), nor increase thrombin
generation when added to plasma, as demonstrated by
thrombin generation assays. In in vitro platelet aggregation
studies, idarucizumab did not induce platelet aggregation
alone or affect protease-activated receptor 1einduced
platelet aggregation by the thrombin receptor-activating
peptide SFLLRN.8PRECLINICAL ASSESSMENT OF IDARUCIZUMAB’S
REVERSAL OF DABIGATRAN’S ANTICOAGULANT
ACTIVITY
The reversal effects of intravenous idarucizumab were
investigated in rats treated with dabigatran when both were
given in equimolar concentration.8 Dabigatran alone
prolonged thrombin time (TT) by 4-fold and activated par-
tial thromboplastin time (aPTT) by 2-fold, over controls.
This anticoagulant activity was completely reversed by
idarucizumab within 1 minute of administration.
The ability of idarucizumab to reverse dabigatran’s
anticoagulant effects was compared with the effects of
nonspeciﬁc procoagulant strategies by using in vitro studies
of platelet and coagulation responses to vessel injury under
ﬂow conditions.16 Dabigatran added in vitro to human blood
from healthy donors reduced ﬁbrin coverage by 85% and
platelet deposition by 35%. Dabigatran also altered the
dynamics of thrombin generation, prolonging the lag-phase
and reducing the maximal thrombin peak and thrombin
generation, as well as prolonging clotting time (CT) and clot
formation time (CFT). These effects were completely
reversed with the addition of idarucizumab (0.3, 1, and
3 mg/mL). In contrast, prothrombin complex concentrates
(PCCs; 70 IU/kg) and activated PCCs (aPCCs; 25 and
75 IU/kg) only partially reversed dabigatran-associated
changes in ﬁbrin deposition, CT, and CFT, as well as
increasing thrombin generation levels beyond those of pre-
dabigatran levels.
The reversal effects of idarucizumab (30 and 60 mg/kg)
were compared with PCC (30 and 60 IU/kg), aPCC (30 and
60 IU/kg), and recombinant FVIIa (90 and 180 mg/kg)
ex vivo in a blunt liver trauma porcine model.17 Dabigatran
etexilate (oral 30 mg twice daily for 3 days; followed by
intravenous infusion of 0.77 mg/kg/h for 30 minutes and
0.52 mg/kg/h for 60 minutes) was administered to the
animals before injury to achieve consistent supratherapeutic
plasma concentrations as demonstrated by prolonged
prothrombin time (PT), aPTT, CT, and CFT. When idar-
ucizumab was added to ex vivo blood samples, the coag-
ulation parameters were corrected, as demonstrated by the
restoration of PT, aPTT, CT, and CFT to baseline levels.
Prothrombin complex concentrates and aPCC reduced the
anticoagulant effects of dabigatran but to a lesser extent
than idarucizumab, as demonstrated by signiﬁcant
decreases in PT, CT, and CFT, with no effect on aPTT.
Thrombin
MW ~ 37 kDaltons
Dabigatran
MW 472
Idarucizumab
MW ~ 48 kDaltons
Figure 1 Structure and relative sizes of thrombin (FIIa), dabigatran, and idarucizumab. Reprinted
with permission from Pollack et al.14
Figure 2 Effects of posttrauma idarucizumab on blood loss
in animals treated with dabigatran. Reprinted with permission
from Elsevier from Grottke et al.18 The dashed vertical line
(t ¼ 0) indicates time of liver injury, and the dotted vertical
line indicates the time of intervention (t ¼ 15 minutes). Data
are shown as mean  SD, n ¼ 6 per group; *P < .05 versus
all groups. IDA ¼ idarucizumab.
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parameters. Idarucizumab, unlike PCC and aPCC, also
reduced the mean plasma concentrations of unbound
dabigatran (measured by dTT) to below the limit of
quantitation.
In vivo administration of idarucizumab also reduced
dabigatran-associated bleeding and mortality in a porcine
trauma model.18 Animals were treated with supratherapeutic
doses of dabigatran (dosed as described above) before
treatment with idarucizumab (30, 60, or 120 mg/kg), and
blood loss and hemodynamic variables were monitored for
up to 4 hours after injury. Anticoagulation with dabigatran
resulted in signiﬁcantly higher blood loss than in non-
anticoagulated animals and a 100% mortality (Figure 2).18
Idarucizumab immediately reversed the anticoagulant
effects of dabigatran and was associated with a signiﬁcant
reduction in blood loss when administered 15 minutes after
trauma; bleeding stopped within 15 minutes of treatment.
In a dose-dependent fashion, the lowest dose (30 mg/kg)
reduced blood loss by 47% and resulted in an 83% reduction
in mortality, and all animals that received 60 or 120 mg/kg
idarucizumab survived, with total blood loss being reduced
by 64% and 62%, respectively. All coagulation tests were
also restored to baseline in a dose-dependent manner, with
the highest dose of idarucizumab (120 mg/kg) restoring
coagulation for the duration of the study, and thrombin
generation normalized dose-dependently after idarucizumab
administration.
Four-factor PCC (50 or 100 IU/kg) and aPCC (50 IU/kg)
have also been shown to be effective in reducing dabigatran-associated blood loss and improving coagulation in a
polytrauma porcine model, although the coagulation tests,
such as aPTT, dTT, and ecarin clotting time (ECT), poorly
reﬂected the effects of either PCC or aPCC treatment on
dabigatran anticoagulation.19,20 The reduction of dabigatran-
associated blood loss with PCC was dose-dependent
Figure 3 (A) Effect of increasing doses of prothrombin
complex concentrate (PCC) on reducing dabigatran-
associated bleeding. (B) Thrombin-antithrombin complex
(TAT) was also measured over time. Data shown as mean 
SD, n ¼ 8 per group; *P < .05.
Figure 4 Geometric mean idarucizumab plasma
concentration-time proﬁles from the start of a single infusion
of 1 g to 4 g idarucizumab for 5 minutes on (A) a linear scale
and (B) a semi-log scale. Reprinted with permission from
Glund et al.21
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IU/kg had no effect on blood loss (Figure 3). There was also
an elevated state of coagulation and hyperﬁbrinolysis with
increasing doses of PCC, measured as increased thrombin
generation, thrombineantithrombin complex, and D-dimer
levels.19 The lower dose of both PCC and aPCC (25 IU/kg)
did not produce sustained procoagulant effects and also did
not reduce blood loss.19,20 Thus, this suggests sufﬁcient
thrombin generation to overcome the dabigatran anticoagu-
lant effect is required to control bleeding; however, excessive
thrombin generation can further shift the balance to a pro-
coagulant state.EARLY CLINICAL EVIDENCE FOR IDARUCIZUMAB
Idarucizumab has been evaluated in healthy male volunteers
in a phase 1 randomized, placebo-controlled study
(NCT0168830), which comprised 2 parts: a single rising-
dose evaluation of the safety, tolerability, and pharmacoki-
netics of idarucizumab alone (part 1) and a dose-ﬁnding,
proof-of-concept assessment of idarucizumab in subjects
pretreated with dabigatran etexilate (part 2).15,21 The phar-
macokinetics and reversal effects of idarucizumab have alsobeen evaluated in middle-aged and elderly individuals and
those with mild or moderate renal impairment in a separate
randomized, double-blind, 2-way cross-over phase 1b
study.22Pharmacokinetics
In part 1 of the ﬁrst phase 1 trial, 110 male healthy vol-
unteers (aged 18-45 years) received single doses of intra-
venous idarucizumab (1-hour infusion: 20 mg to 8 g;
5-minute infusion: 1 g, 2 g, and 4 g) or placebo.21 Peak
plasma concentrations were achieved at or shortly after the
end of the 1-hour or 5-minute infusions. Both geometric
mean peak exposure (Cmax) and total exposure (AUC0-N)
increased with increasing dose (Figure 4). The geometric
mean initial half-life across doses was 39-54 minutes, and
the geometric mean terminal half-life for doses 600 mg
was 4.5-8.1 hours. After infusion, geometric mean idar-
ucizumab plasma concentrations rapidly declined, reaching
4% of peak concentrations at 4 hours. This corresponded
with the observed idarucizumab renal excretion predomi-
nantly occurring in the ﬁrst 4-hour collection period.
Together with a limited distribution (approximating blood
volume), this suggests that the decline in plasma concen-
trations of idarucizumab was predominantly due to renal
elimination. The fact that the majority of the idarucizumab
renal excretion occurred in the ﬁrst 4 hours after infusion
may account for a transient increase in urinary protein,
which occurred in a dose-related manner after doses of
S68 The American Journal of Medicine, Vol 129, No 11A, November 20161 g (discussed further in the “Safety” section below).
Trace amounts of idarucizumab were found in the plasma
for up to 16 hours after the 1-g infusion and up to 24 hours
after higher doses.Figure 5 Effect of idarucizumab or placebo infusion on coa
TT, by dose group Reprinted with permission from Elsevier
limit of normal. “0 h” and the arrows on x axes show when
izontal lines show the mean baseline measurement. Data
aPTT ¼ activated partial thromboplastin time; DE ¼ d
ECT ¼ ecarin clotting time.Reversal of Dabigatran Anticoagulant Activity
Part 2 of the above study assessed the reversal of the antico-
agulant effects of dabigatran by idarucizumab (single
5-minute infusion of 1 g, 2 g, or 4 g, or 2 5-minute infusionsgulation variables, (A) dTT, (B) ECT, (C) aPTT and (D)
from Glund et al.15 Dotted horizontal lines show upper
the idarucizumab or placebo infusion ended. Solid hor-
points show mean; error bars show standard error.
abigatran etexilate; dTT ¼ diluted thrombin time;
Figure 6 Plasma concentration of unbound dabigatran after
infusion of placebo or idarucizumab. Reprinted with
permission from Elsevier from Glund et al.15 Dabigatran
etexilate was administered at 2 hours (arrows) on the x axis
on days 3 and 4. Placebo or idarucizumab infusion ended at
0 h (arrow) on the x axis on day 4 (end of ﬁrst infusion for the
5-g þ 2.5-g group). Data points show geometric mean values.
DE ¼ dabigatran etexilate.
Reilly et al Idarucizumab: MOA/phase 1 Data S69of 5 g þ 2.5 g 1 hour apart). Individuals were pretreated to
dabigatran steady-state with dabigatran etexilate 220 mg
twice daily for 3 days, followed by a ﬁnal dose on day 4,15 a
dosing regimen that resulted in mean peak dabigatran con-
centrations in the healthy volunteers that were similar to
corresponding levels in patients in the Randomized
Evaluation of Long-term anticoagulation therapY (RE-LY)
study who received dabigatran 150 mg twice daily.23
All doses of idarucizumab resulted in immediate and
complete reversal of dabigatran anticoagulant activity, as
indicated by a normalization of coagulation times directly after
the end of infusion, including coagulation measurements of
dTT, ECT, aPTT, and TT.15 For doses 2 g this effect was
sustained over the entire observation period of 72 hours
(Figure 5), although small increases in the highly sensitive TT
above the upper limit of normal were observed with the 2-g
(2 hours after dose) and 4-g (12-24 hours after dose) idar-
ucizumabdoses (but not 5 gþ 2.5g). Thismaybe explainedby
the narrow normal range for TT resulting from low variability
of baseline TT clotting times in these healthy individuals, as
well as the high sensitivity of TT for dabigatran.
The reversal effect of idarucizumab was quantiﬁed by
calculating the ratio of the day-4 area under the dabigatran-
effect curve over 2-12 hours after dabigatran administration
(AUEC2-12) to the day-3 AUEC2-12. For dTT, idarucizumab
(1 g, 2 g, 4 g, and 5 g þ 2.5 g) reduced this ratio by 74%,
94%, 98%, and 99%, respectively. The dTT and ECT
seemed to be the most suitable assays for assessing the
anticoagulant activity of dabigatran and its reversal by
idarucizumab, on the basis of the low variability of baseline
clotting times and close correlation with unbound dabigatran
concentration (ie, dabigatran not bound to idarucizumab or
plasma proteins; R2 ¼ 0.86 and R2 ¼ 0.89, respectively).
Unbound dabigatran was determined by ultraﬁltration of
plasma followed by high-performance liquid chromatog-
raphy tandem mass spectrometry, and can be considered a
rough measure of pharmacologically active dabigatran.
Increases in total dabigatran plasma concentrations
(ie, bound and unbound dabigatran, including active me-
tabolites) were observed immediately after idarucizumab
dosing, which can be attributed to the peripheral distribution
of dabigatran and idarucizumab’s mode of action (ie, spe-
ciﬁc binding and neutralization of dabigatran). The increase
in total dabigatran plasma concentrations then results from
the redistribution of unbound dabigatran from the periphery
to the central compartment. Because idarucizumab has a
small volume of distribution at steady state (Vss, 8.9 L) it is
mostly conﬁned to the plasma compartment.12 In contrast,
dabigatran has a larger volume of distribution
(Vss, 50-70 L)
1 and is, therefore, distributed between the
plasma compartment and the periphery, in a dynamic equi-
librium. After idarucizumab infusion, dabigatran in the
plasma compartment is promptly neutralized via idar-
ucizumab binding, resulting in a decrease in unbound dabi-
gatran plasma concentration. Dabigatran then redistributes
from the periphery to the plasma compartment to maintain
the equilibrium, as long as free idarucizumab is present.Directly after idarucizumab infusion in this study, geo-
metric mean concentrations of unbound dabigatran were at or
close to lower limit of quantiﬁcation (LLOQ; 1 ng/mL) and
remained <10 ng/mL after the 2-g dose and <5 ng/mL after
the 4-g and 5-g þ 2.5-g doses over 72 hours (Figure 6).15
Active dabigatran plasma concentrations (as measured by
the calibrated dTT assay, HEMOCLOT; HYPHEN BioMed,
Neuville-sur-Oise, France) also decreased to and remained
<50 ng/mL (LLOQ) over 72 hours after the 2-g, 4-g, and
5-g þ 2.5-g doses of idarucizumab.
Although this study did not measure the effect of idar-
ucizumab on bleeding, a potential bleeding marker was
evaluated. Measurement of FPA levels at a wound site
represents an indirect measure of local activation of coag-
ulation, because FPA is released upon ﬁbrinogen conversion
to ﬁbrin, and thus, levels are raised at wound sites. There-
fore, the effect of idarucizumab on restoring ﬁbrin genera-
tion at a nonpenetrating wound site in individuals pretreated
with dabigatran was evaluated by measuring FPA levels in
blood shed from the incision site. After 3 days of dabigatran
treatment, levels of FPA decreased by 87% (2.5 hours after
dose) and 73% (6 hours after dose). Increasing doses of
idarucizumab resulted in dose-dependent increases in ﬁbrin
formation, returning FPA to 24% to 95% of predabigatran
levels 30 minutes after idarucizumab administration.
S70 The American Journal of Medicine, Vol 129, No 11A, November 2016Effect of Renal Function on the
Pharmacokinetics/Pharmacodynamics of
Idarucizumab
The pharmacokinetics and reversal effects of idarucizumab
in middle-aged and elderly individuals were compared with
those in individuals with mild or moderate renal impairment
(creatinine clearance: 60 to <90 [n ¼ 12] or 30 to <60 mL/
min [n ¼ 6], respectively) in a separate randomized, double-
blind, 2-way cross-over phase 1b study (N ¼ 46).12,22
Participants were pretreated with dabigatran etexilate
(healthy volunteers: 220 mg twice daily; renally impaired:
150 mg twice daily) and then received a 5-minute intrave-
nous infusion of idarucizumab (1 g, 2.5 g, 5 g, or 2  2.5 g).
Compared with healthy individuals, the total clearance
was reduced in individuals with renal impairment, which
resulted in an increase in idarucizumab’s area under the
curve by 43.5% and 83.5% in those with mild and moderate
renal impairment, respectively.
Renal impairment and old age, however, were not found to
impact the reversal effect of idarucizumab.22 In healthy and
elderly volunteers and those with renal impairment, idar-
ucizumab completely reversed dabigatran anticoagulant
activity by the end of the 5-minute infusion, as demonstrated
by unbound dabigatran levels near the LLOQ and a return of
prolonged clotting times to baseline levels, which was
sustained for doses 2.5 g. A second administration of idar-
ucizumab2months after theﬁrst infusion in healthy volunteers
also completely reversed dabigatran-induced anticoagulation,
and 24 hours after idarucizumab, dabigatran etexilate could be
administered to re-establish anticoagulation.24Lack of Antithrombotic or Prothrombotic
Properties
In the ﬁrst phase 1 study, idarucizumab (8 g infused over
1 hour or 4 g infused over 5 minutes) administered alone
had no effect on coagulation parameters (dTT, ECT, TT,
aPTT, and activated clotting time) measured 15 minutes
after the end of the infusion (ie, at peak plasma levels).21
Furthermore, these doses of idarucizumab did not affect
endogenous thrombin formation.21 Similarly, in part 2 of
this trial when idarucizumab (at doses 2 g) fully inhibited
dabigatran anticoagulant activity, thrombin generation var-
iables were restored to pre-dabigatran levels but did not
exceed these baseline values.15 These ﬁndings conﬁrm the
in vitro data indicating the lack of any antithrombotic or
prothrombotic properties of idarucizumab.8Safety
Idarucizumab was well tolerated in each of the phase 1 trials
described above, with no relationships observed between
idarucizumab dose and adverse event frequency. There were
no severe or serious adverse events, no dose-related events,
and no discontinuations due to adverse events.15,21,22 In the
ﬁrst phase 1 study, no clinically relevant differences were
reported regarding the overall incidence of adverse eventsbetween the placebo and idarucizumab groups.21 Five
individuals (placebo, n ¼ 2; idarucizumab, n ¼ 3) were
reported to have adverse events that were considered to be
drug-related by the investigator. With the exception of
1 case of migraine of moderate intensity, which occurred in
an individual who received idarucizumab 8 g, all drug-
related adverse effects were mild. In the idarucizumab-
treated individuals, they comprised headache (n ¼ 2),
erythema (n ¼ 1), and migraine (n ¼ 1), and in the placebo
group, pain in extremity (n ¼ 1) and upper abdominal and
chest pain (n ¼ 1). Local infusion-site reactions (mild
erythema, swelling, redness, and pain) were limited to those
in the 1-hour infusion group. No clinically relevant ﬁndings
were reported for laboratory parameters, vital signs, elec-
trocardiogram, cardiac telemetry, and physical examination.
A transient, dose-dependent increase in low molecular
weight protein excretion in urine was observed in
individuals receiving idarucizumab. This effect was
considered to be secondary to saturation of the renal tubular
uptake process for small proteins, and there were no
corresponding changes suggesting acute tubular injury or
loss of function. All values of urinary protein excretion
normalized within 4-12 hours after the infusion.
Similarly, in part 2 of this trial, no unexpected or clinically
relevant safety concerns for idarucizumab were observed.15
Adverse events considered to be drug related were infusion
site erythema and hot ﬂushes in a subject who received
dabigatran plus idarucizumab 1 g, epistaxis in a subject who
received dabigatran plus idarucizumab 5 g þ 2.5 g, and
infusion site hematoma in a subject receiving dabigatran plus
placebo. All these adverse events were of mild intensity.Immunogenicity
There is a potential for immunogenicity with idarucizumab
as with all proteins. Immunogenicity was therefore evalu-
ated using an electro-chemiluminescence-based assay and
plasma samples from 283 individuals, of whom 224 were
treated with idarucizumab.12,25 Pre-existing antibodies
(ie, those detected in baseline samples) with cross-reactivity
to idarucizumab were detected in 33 of the 283 individuals
(12%).25 Most of these pre-existing antibodies had low
titers, and there was no impact on the pharmacokinetics or
the reversal effect of idarucizumab or hypersensitivity
reactions in individuals with pre-existing antibodies. Nine
individuals treated with idarucizumab (4%) had a low titer,
treatment-emergent, possibly persistent anti-idarucizumab
antibody response.
The epitope speciﬁcity of antibodies to idarucizumab was
determined with probe molecules. None of the pre-existing
antibodies interacted with the dabigatran-binding region of
idarucizumab. Similarly, the majority of the treatment-
emergent antibodies had speciﬁcity for the C-terminus,
which is not a region that dabigatran binds to. Of the
remaining treatment-emergent antibodies, 2 of 19 (10%) had
speciﬁcity for the idarucizumab variable region, 2 (10%) had
mixed speciﬁcity, and 1 (5%) had undetermined speciﬁcity.25
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Selection of the idarucizumab dose for clinical use was
based on the goal of neutralizing the total body load of
dabigatran in patients with atrial ﬁbrillation. The binding
stoichiometry between idarucizumab and dabigatran is 1:1,
that is, 1 molecule of idarucizumab binds 1 molecule of
dabigatran. Total body load of dabigatran can be estimated
from the plasma concentrations and the apparent volume of
distribution. On the basis of the average peak concentrations
of dabigatran observed in patients with atrial ﬁbrillation who
received dabigatran 150 mg twice daily in the RE-LY study
(which enrolled a cohort of patients aged 65 years with a
moderate-to-high comorbidity burden), it was calculated
that a dose of 2 g of idarucizumab would completely bind
the total body load of dabigatran in patients at the 70th
percentile of dabigatran concentrations (ie, this dose would
result in full reversal of dabigatran effects in 70% of
patients).21,23,26 However, higher doses of idarucizumab
may be required to achieve full reversal in some patients
because the peak dabigatran concentrations in the RE-LY
study varied by more than 5-fold.21,23 Additionally,
patients with bleeding and those with renal impairment may
have higher dabigatran concentrations than those without
bleeding or renal impairment. Therefore, 5 g was chosen as
a dose that was estimated to reverse the 99th percentile of
concentrations observed in the RE-LY study in patients with
moderate renal dysfunction.27,28 Such a dose should cover
the vast majority of patients in clinical practice. In the phase
1 study involving male and female individuals of different
ages and renal function, administration of 5-g or 2  2.5-g
doses of idarucizumab resulted in sustained reversal of
dabigatran-induced anticoagulation.22 Therefore a total dose
of 5 g idarucizumab has been selected as the dose for further
clinical testing.CONCLUSIONS
Idarucizumab, a humanized anti-dabigatran Fab, binds
dabigatran with a fast on and slow off rate, resulting in
almost irreversible binding, with a binding afﬁnity 350-fold
higher than dabigatran’s afﬁnity for thrombin. As a result,
idarucizumab binds free and thrombin-bound dabigatran,
neutralizing its anticoagulant activity. In animal bleeding
models, idarucizumab reversed the anticoagulant effects of
dabigatran and stopped the bleeding. Immediate and com-
plete reversal of the anticoagulant effects of dabigatran by
idarucizumab has also been demonstrated in healthy young
volunteers with normal renal function, elderly volunteers
aged 65-80 years, and in volunteers aged 45-80 years with
mild or moderate renal impairment. After intravenous
infusion in volunteers, idarucizumab concentrations peak
within minutes, followed by rapid elimination. In the
absence of dabigatran, idarucizumab has no effect on
coagulation parameters or thrombin formation. It was well
tolerated at all administered doses in the phase 1 trials.
These preclinical and early clinical data suggest that idar-
ucizumab may provide a safe and effective means ofreversing anticoagulant activity in emergency situations in
patients treated with dabigatran.References
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